DE10223783A1 - Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers - Google Patents

Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers

Info

Publication number
DE10223783A1
DE10223783A1 DE10223783A DE10223783A DE10223783A1 DE 10223783 A1 DE10223783 A1 DE 10223783A1 DE 10223783 A DE10223783 A DE 10223783A DE 10223783 A DE10223783 A DE 10223783A DE 10223783 A1 DE10223783 A1 DE 10223783A1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
biii
cyclodextrin
acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10223783A
Other languages
German (de)
English (en)
Inventor
Bernd Kruss
Claus Veit
Klaus Wagner
Jean Marie Stassen
Karin Ruehr
Annerose Mauz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE10223783A priority Critical patent/DE10223783A1/de
Priority to AT03735445T priority patent/ATE373492T1/de
Priority to EP03735445A priority patent/EP1511517B1/de
Priority to ES03735445T priority patent/ES2294295T3/es
Priority to CA002487150A priority patent/CA2487150A1/en
Priority to PCT/EP2003/005399 priority patent/WO2003099336A1/de
Priority to AU2003237664A priority patent/AU2003237664A1/en
Priority to JP2004506859A priority patent/JP2005527615A/ja
Priority to DE50308227T priority patent/DE50308227D1/de
Priority to PE2003000511A priority patent/PE20040066A1/es
Priority to UY27823A priority patent/UY27823A1/es
Priority to ARP030101863A priority patent/AR040134A1/es
Priority to US10/446,611 priority patent/US6828311B2/en
Priority to TW092114414A priority patent/TW200400029A/zh
Publication of DE10223783A1 publication Critical patent/DE10223783A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE10223783A 2002-05-29 2002-05-29 Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers Withdrawn DE10223783A1 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
DE10223783A DE10223783A1 (de) 2002-05-29 2002-05-29 Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers
AT03735445T ATE373492T1 (de) 2002-05-29 2003-05-23 Formulierung zur parenteralen applikation eines na-kanal-blockers
EP03735445A EP1511517B1 (de) 2002-05-29 2003-05-23 Formulierung zur parenteralen applikation eines na-kanal-blockers
ES03735445T ES2294295T3 (es) 2002-05-29 2003-05-23 Formulacion para la administracion parenteral de un bloqueador del canal na.
CA002487150A CA2487150A1 (en) 2002-05-29 2003-05-23 New formulation for parental application of sodium channel blocker
PCT/EP2003/005399 WO2003099336A1 (de) 2002-05-29 2003-05-23 Formulierung zur parenteralen applikation eines na-kanal-blockers
AU2003237664A AU2003237664A1 (en) 2002-05-29 2003-05-23 Formulation for parenteral administration of sodium channel blockers
JP2004506859A JP2005527615A (ja) 2002-05-29 2003-05-23 ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤
DE50308227T DE50308227D1 (de) 2002-05-29 2003-05-23 Formulierung zur parenteralen applikation eines na-kanal-blockers
PE2003000511A PE20040066A1 (es) 2002-05-29 2003-05-27 NUEVA FORMULACION PARA LA ADMINISTRACION PARENTERAL DE UN BLOQUEANTE DEL CANAL DEL Na
UY27823A UY27823A1 (es) 2002-05-29 2003-05-27 Nueva formulación para la administración parenteral de un bloqueante del canal del na
ARP030101863A AR040134A1 (es) 2002-05-29 2003-05-28 Formulacion para la administracion parenteral de un bloqueante del canal del na
US10/446,611 US6828311B2 (en) 2002-05-29 2003-05-28 Formulation for the parenteral application of a sodium channel blocker
TW092114414A TW200400029A (en) 2002-05-29 2003-05-28 New formulation for the parenteral application of a sodium channel blocker

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10223783A DE10223783A1 (de) 2002-05-29 2002-05-29 Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers

Publications (1)

Publication Number Publication Date
DE10223783A1 true DE10223783A1 (de) 2003-12-11

Family

ID=29432393

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10223783A Withdrawn DE10223783A1 (de) 2002-05-29 2002-05-29 Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers
DE50308227T Expired - Fee Related DE50308227D1 (de) 2002-05-29 2003-05-23 Formulierung zur parenteralen applikation eines na-kanal-blockers

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50308227T Expired - Fee Related DE50308227D1 (de) 2002-05-29 2003-05-23 Formulierung zur parenteralen applikation eines na-kanal-blockers

Country Status (12)

Country Link
EP (1) EP1511517B1 (es)
JP (1) JP2005527615A (es)
AR (1) AR040134A1 (es)
AT (1) ATE373492T1 (es)
AU (1) AU2003237664A1 (es)
CA (1) CA2487150A1 (es)
DE (2) DE10223783A1 (es)
ES (1) ES2294295T3 (es)
PE (1) PE20040066A1 (es)
TW (1) TW200400029A (es)
UY (1) UY27823A1 (es)
WO (1) WO2003099336A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DE4313408A1 (de) * 1993-04-23 1994-10-27 Boehringer Mannheim Gmbh Cyclodextrin-Biocid-Komplex
FR2713934B1 (fr) * 1993-12-22 1996-01-12 Commissariat Energie Atomique Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives.
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2415131A1 (en) * 2000-07-24 2002-01-31 Boehringer Ingelheim Pharmaceuticals, Inc. Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
DE10223784A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation von Crobenetine

Also Published As

Publication number Publication date
UY27823A1 (es) 2003-12-31
ATE373492T1 (de) 2007-10-15
JP2005527615A (ja) 2005-09-15
TW200400029A (en) 2004-01-01
PE20040066A1 (es) 2004-03-22
EP1511517A1 (de) 2005-03-09
DE50308227D1 (de) 2007-10-31
AR040134A1 (es) 2005-03-16
ES2294295T3 (es) 2008-04-01
AU2003237664A1 (en) 2003-12-12
CA2487150A1 (en) 2003-12-04
WO2003099336A1 (de) 2003-12-04
EP1511517B1 (de) 2007-09-19

Similar Documents

Publication Publication Date Title
DE69727218T2 (de) Einschlusskomplexe von aryl-heterozyklischen salzen
EP0794767B1 (de) Stabile budesonid-lösungen, verfahren zu deren herstellung sowie verwendung dieser lösungen als klistierzubereitungen und pharmazeutische schäume
DE69109021T2 (de) Augentropfenarzneimittel.
DE69839224T2 (de) Pharmazeutische zusammensetzung enthaltend cyclodextrine und taxoide
DE602004000982T2 (de) Intranasale formulierung mit rotigotin
DE602005002495T2 (de) Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat
DE3346123A1 (de) Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
EP1515740B1 (de) Flüssige zubereitung enthaltend oligopeptide und verethertes cyclodextrin
DE69730902T2 (de) Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes
DE60305438T2 (de) Lyophilisierte pharmazeutische zusammensetzung von propofol
EP0435826A1 (de) Intravenöse Lösungen für Status Epilepticus
DE60305813T2 (de) Stabile Oxazaphosphorin-2-Mercaptoethansulphonat Formulierungen
DE112016005058T5 (de) Neue Levothyroxin-Formulierungen zur oralen Anwendung
DE60018744T2 (de) Komplex von Eletriptan und Sulfobutylether-cyclodextrin und dessen Verwendung zur Behandlung von Migräne
EP1511517B1 (de) Formulierung zur parenteralen applikation eines na-kanal-blockers
EP2234614B1 (de) Pharmazeutische zusammensetzung zur parenteralen verabreichung eines ultrakurzwirksamen beta-adrenorezeptor antagonisten
DD296841A5 (de) Intravenoese loesungen mit schnellem wirkungseintritt
US6828311B2 (en) Formulation for the parenteral application of a sodium channel blocker
DE202018103853U1 (de) Zusammensetzung zur Applikation von Curcumin
EP1496859B1 (de) Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat
WO2007057005A1 (de) Lipopeptid zusammensetzungen
DE69001988T2 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
DE102004006048B4 (de) Intravenös zu verabreichende Injektions-oder Infusionslösung enthaltend ein Kombinationsarzneimittel zur Verwendung als konstrastverstärkendes Mittel in der MR Angiographie
US20040072797A1 (en) Storage stable eplerenone formulation
DE69016381T2 (de) Behandlung von männlichen, hormonabhängigen Krankheiten mit Cyclodextrinen und Derivaten davon.

Legal Events

Date Code Title Description
8141 Disposal/no request for examination